Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Study of VA Combined With PD-1 Inhibitor in the Treatment of Relapsed and Refractory AML and High-risk MDS

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06536959
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:18.564869+00:00
Published At
2024-08-05T00:00:00+00:00
Record Updated At
2024-08-05
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Relapsed Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Minimal Residual Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-08-05"
protocolSection.identificationModule.nctId
"NCT06536959"
protocolSection.identificationModule.officialTitle
"A Study of VA Combined With PD-1 Inhibitor in the Treatment of Relapsed and Refractory AML and High-risk MDS"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Relapsed Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Minimal Residual Disease (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.